<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009329</url>
  </required_header>
  <id_info>
    <org_study_id>JAB-21822-1002</org_study_id>
    <nct_id>NCT05009329</nct_id>
  </id_info>
  <brief_title>FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China</brief_title>
  <official_title>Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12c Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobio Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jacobio Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety, tolerability, PK, preliminary efficacy and determine recommended phase 2&#xD;
      dose (RP2D) of JAB-21822 administered in adult participants with KRAS p.G12C-mutant advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2a, first-in-human, open-label study of JAB-21822, this study has two&#xD;
      parts: dose escalation phase and dose expansion phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) in the dose escalation phase</measure>
    <time_frame>first 21 days</time_frame>
    <description>Number of participants with dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Cmax of JAB-21822 will be measured by using plasma PK samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate ( ORR )</measure>
    <time_frame>up to 4 years</time_frame>
    <description>ORR is defined as the proportion of participants with complete response or partial response (CR+PR) per RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response ( DOR )</measure>
    <time_frame>up to 4 years</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate ( DCR )</measure>
    <time_frame>up to 4 years</time_frame>
    <description>DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease(SD) per CTCAE v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per CTCAE v1.1 or death which occurs first</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>NSCLC</condition>
  <condition>CRC</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of JAB-21822 to determine maximum tolerated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditionally required</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-21822</intervention_name>
    <description>JAB-21822 will be administered orally</description>
    <arm_group_label>Phase 1 Dose Exploration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-21822</intervention_name>
    <description>JAB-21822 will be administered orally</description>
    <arm_group_label>Phase 1 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, with failure or&#xD;
             absence of standard treatment&#xD;
&#xD;
          3. Subject must be ≥18 years&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.&#xD;
&#xD;
          5. Subjects with life expectancy ≥3 months.&#xD;
&#xD;
          6. Subjects must have at least one measurable lesion as defined by RECIST v1.1.&#xD;
&#xD;
          7. There was no serious organ dysfunction in the screening stage&#xD;
&#xD;
          8. Male or female subjects of reproductive age agree to use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of intestinal disease or major gastric surgery or inability to swallow oral&#xD;
             medications&#xD;
&#xD;
          2. Other active cancer&#xD;
&#xD;
          3. Previously treated with KRAS G12C inhibitor&#xD;
&#xD;
          4. Active infection including hepatitis B, hepatitis C and human immunodeficiency virus&#xD;
             (HIV)&#xD;
&#xD;
          5. Impaired heart function or clinically significant heart disease&#xD;
&#xD;
          6. Pregnant or breast-feeding&#xD;
&#xD;
          7. Previous allogeneic bone marrow transplant or organ transplant&#xD;
&#xD;
          8. Intended study subjects who were unable to abstain from alcohol during medication&#xD;
&#xD;
          9. Other unqualified conditions judged by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacobio Pharmaceuticals</last_name>
    <phone>86 10 56315466</phone>
    <email>clinicaltrials@jacobiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS G12C Mutant Advanced Solid Tumor; NSCLC; CRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

